Journal
INTERNAL MEDICINE
Volume 48, Issue 15, Pages 1307-1309Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.48.1926
Keywords
rheumatoid arthritis; tocilizumab; leukoencephalopathy; cognitive impairment; MRI; interleukin 6
Categories
Ask authors/readers for more resources
The biological agent tocilizumab, is a humanized, anti-human interleukin-6 receptor antibody. A 72-year-old woman developed cognitive impairment during the Phase III clinical trial of tocilizumab for the treatment of rheumatoid arthritis. MRI demonstrated hyperintense dissemination throughout the white matter on T2WI. An initial diagnosis of possible progressive multifocal leukoencephalopathy was made, but the PCR for JC virus DNA was negative in the CSF. The leukoencephalopathy might have been caused by a mechanism related to tocilizumab itself. It is strongly recommended to perform MRI if a patient develops any cognitive impairment during tocilizumab therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available